No headlines found.
Applied Therapeutics Files Form 12b-25 with the Securities and Exchange Commission
Globe Newswire (Mon, 31-Mar 7:12 AM ET)
Applied Therapeutics Appoints Todd F. Baumgartner, MD, MPH as Chief Regulatory Officer
Globe Newswire (Wed, 19-Mar 7:00 AM ET)
Globe Newswire (Tue, 18-Feb 2:22 PM ET)
Business Wire (Tue, 18-Feb 11:53 AM ET)
Globe Newswire (Tue, 18-Feb 11:12 AM ET)
Globe Newswire (Tue, 18-Feb 8:36 AM ET)
PRNewswire (Tue, 18-Feb 5:45 AM ET)
Globe Newswire (Mon, 17-Feb 12:52 PM ET)
PRNewswire (Mon, 17-Feb 6:01 AM ET)
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes, AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.
Applied Therapeutics trades on the NASDAQ stock market under the symbol APLT.
As of April 7, 2025, APLT stock price declined to $0.41 with 3,472,064 million shares trading.
APLT has a beta of 1.13, meaning it tends to be more sensitive to market movements. APLT has a correlation of 0.01 to the broad based SPY ETF.
APLT has a market cap of $47.71 million. This is considered a Sub-Micro Cap stock.
In the last 3 years, APLT traded as high as $10.62 and as low as $.36.
The top ETF exchange traded funds that APLT belongs to (by Net Assets): VTI, IWM, VXF, VTWO, IBB.
APLT has underperformed the market in the last year with a price return of -93.1% while the SPY ETF was flat at -0.3%. APLT has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -56.6% and -28.5%, respectively, while the SPY returned -14.5% and -10.6%, respectively.
APLT support price is $.41 and resistance is $.46 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that APLT shares will trade within this expected range on the day.